Novartis AG 2021 IR
The report highlights Novartis' financial and ESG performance for the fiscal year 2021. The company achieved net sales of USD 51.6 billion and reached 766 million patients with its medicines. Key highlights include delivering 1 billion antimalarial treatments since 1999 and reducing Scope 1 and Scope 2 greenhouse gas emissions by 34% compared to the 2016 baseline. Novartis also launched its first Integrated Report, combining its ESG Report and Annual Review, and committed to achieving net-zero carbon emissions across its value chain by 2040.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2021
Type: IR
Pages: 61
Back to company
Novartis AG
Integrated Report
The report highlights Novartis' financial and ESG performance for the fiscal year 2021. The company achieved net sales of USD 51.6 billion and reached 766 million patients with its medicines. Key highlights include delivering 1 billion antimalarial treatments since 1999 and reducing Scope 1 and Scope 2 greenhouse gas emissions by 34% compared to the 2016 baseline. Novartis also launched its first Integrated Report, combining its ESG Report and Annual Review, and committed to achieving net-zero carbon emissions across its value chain by 2040.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees